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This article investigates everyday experiences and practises that are associated with processes of phar-
maceuticalization and with practices of ‘drug diversion’dthat is, the illicit exchange and non-medical use
of prescription drugs. It reports results from a qualitative study that was designed to examine the
everyday dimensions of non-medical prescription stimulant use among students on an American uni-
versity campus, which involved 38 semi-structured interviews with individuals who used prescription
stimulants as a means of improving academic performance. While discussions of drug diversion are often
framed in terms of broad, population-level patterns and demographic trends, the present analysis pro-
vides a complementary sociocultural perspective that is attuned to the local and everyday phenomena.
Results are reported in relation to the acquisition of supplies of medications intended for nonmedical use.
An analysis is provided which identiﬁes four different sources of diverted medications (friends; family
members; black-market vendors; deceived clinicians), and describes particular sets of understandings,
practices and experiences that arise in relation to each different source. Findings suggest that at the level
of everyday experience and practice, the phenomenon of prescription stimulant diversion is charac-
terised by a signiﬁcant degree of complexity and heterogeneity.
© 2014 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
ALEXIS: We were in the same class; she lived down the hall, so
weworked a lot together. I was done, but shewanted me to stay.
She was actually wanting me to study with her, and I was just,
‘I'm tired’. It doesn't take me that long to do my part, and she
had a little bit more trouble, and it took her a little bit longer. So
she was, ‘all right, welldyou can take an Adderall and just stay
up with me in the library!’ And at ﬁrst, when she said it, I was:
‘no, I'm not taking Adderall. I'm just going to go to sleep, and I'll
help you tomorrow.’
Because of the phobia of its being a pill, you automatically as-
sume that you're going to get an out-of-body experience, you're
doing something wrong, and it's just … I've never been pre-
scribed anything, so it just didn't feel right. But then on the other
hand, I didn't have any hesitation [in relation to concerns about
whether taking the pill] would hurt me because I knew so many
other people that were taking it at time, more frequently. So ILtd. This is an open access articlejust was, ‘all right, I’ll help you out’, and popped it. I ended up
taking it just because she was really struggling in the class. And
once I took it, I was, ‘oh, this isn't that bad.’ And it didn't bother
me, and I didn't feel like I was doing anything wrong.
Alexis is a third-year undergraduate science major who regularly
uses Adderallda stimulant medication composed of mixed amphet-
amine salts that is produced by Shire Pharmaceuticals and approved
for use in the treatment of Attention Deﬁcit and Hyperactivity Dis-
order (ADHD) and narcolepsydto help her study more effectively.
Above, she is telling me about how she came to try the drug for the
ﬁrst time, during a study session with one of her classmates. After
several hours of studying, Alexis hadﬁnishedherwork,was tired, and
was ready to call it a day; however, when her friend offers her a tablet
of Adderall to help her get over any tiredness she might feel, Alexis
accepts the offer. And though she tells me that at the time she
considered herself to be someone who ‘would never do that sort of
thing’, she subsequently begins to use the pills as regularly as she can
obtain them, which she does by ‘dropping hints’ to her friend.
Alexis's non-medical use of Adderall is part of a trend that has
been identiﬁed by a range of scholars: the increasing use ofunder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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enhance the mental capacities of ‘normal’ individuals, i.e. those
who are not ill (Kramer, 1992; Parens, 1998; Quintero and Nichter,
2011). While a wide range of prescription medications are
consumed for unapproved, non-therapeutic purposes, the use of
stimulant medications by individualsdparticularly researchers and
university studentsdseeking to boost their abilities to concentrate
and focus on academic work has become one of the main areas of
focus within discussions of enhancement (Arria, 2008; Elnicki,
2013; Maher, 2008). This phenomenon raises a number of ethical
and policymaking questions that have received attention from
bioethicists, such as whether pharmaceutical enhancement con-
stitutes a form of cheating and whether individuals who do not use
pharmaceutical enhancers might experience coercion (S. Bell et al.,
2013; Farah et al., 2004; Greely et al., 2008; Rudski, 2014). It also
raises signiﬁcant issues that have been examined by social scien-
tists, from politicaleeconomic concerns about the scientiﬁc and
commercial choices involved in the development of medications
that blur the boundary between normal and pathological cognition
(Bond, 2009; Moreira et al., 2009; Whitehouse et al., 2005), to
transformations in medical practice and patient expectations
associated with increasing medicalization (Conrad and Leiter,
2004; Coveney et al., 2011).
A growing body of empirical research provides useful insight
into non-medical prescription stimulant use, particularly in the
form of regional and national surveys that examine broad de-
mographic patterns and social attitudes (Hotze et al., 2011; Maher,
2008; Pilkinton and Cannatella, 2012; Teter et al., 2006). In the US
context, signiﬁcant levels of non-medical prescription stimulant
use have been found among university students, with estimates of
lifetime prevalence rates as high as 6.9% (McCabe et al., 2005). At
the same time, variations have been reported across different re-
gions of the country and among different groups of academic in-
stitutions: for example, lifetime prevalence rates of non-medical
prescription stimulant use are reported to be as high as 25% at in-
stitutions located in the American north-east, with more compet-
itive admissions standards (Loe, 2008; Wilens et al., 2008). Further
variations appear among student subpopulations, with greater
prevalence of use among white male students, and members of
fraternities and sororities (Hall et al., 2005; McCabe et al., 2005).
Survey ﬁndings such as those above are crucial for revealing
signiﬁcant demographic and historical trends about non-medical
prescription stimulant use. However, they are limited in their
ability to produce detailed information on the lived experiences
and daily practices of actual users (Loe and Cuttino, 2008; Singh
et al., 2010). It is increasingly recognized that qualitative research
has the capacity to offer distinctive insight in this respect (Lucke,
2012), and although empirical data on the experiences and prac-
tices of everyday users remains somewhat limited (Singh and
Kelleher, 2010; Varga, 2012), ﬁndings from several studies have
been published in recent years (Loe, 2008; Loe and Cuttino, 2008;
Partridge et al., 2013; Vrecko, 2013). This article aims to
contribute to this emerging body of work, presenting ﬁndings from
a qualitative study designed to further understandings of the
everyday dimensions of non-medical prescription stimulant use
among university students seeking to improve their academic
performance.
1.1. Pharmaceutical leakage: drug diversion and everyday life
Qualitative research on prescription stimulant use among uni-
versity students to date has largely focused on exploring the sub-
jective views and experiences of this population. For example, Loe
and Cuttino (2008)'s study of students diagnosed with ADHD fo-
cuses on forms of identity management and self-conceptionassociated with medication use, while Partridge et al. (2013)
examine perceptions of drug efﬁcacy and safety, and Vrecko
(2013) reports on non-medical users' accounts of experiences of
studying while on prescription stimulants. This article takes a
rather different focus, however, exploring processes associated
with prescription drug ‘diversion’, that is, the movement of medi-
cations away from those to whom they have been prescribed le-
gally, to those who obtain and use them illegally and for non-
therapeutic purposes.
In recent decades, the non-medical use of prescription drugs has
been identiﬁed as a signiﬁcant and growing phenomenon, and has
received increasing attention from public health experts, medical
practitioners, and government agencies involved in law enforce-
ment and drug abuse prevention. While there is some emerging
data on national trends in stimulant drug diversion (McCabe et al.,
2014; Varga, 2012), relatively little is known about the transactions
that arise as prescription stimulants enter into and circulate within
networks of non-medical users (Fischer et al., 2010; Wilens et al.,
2008). Much of existing research and commentary relating to
drug diversion has been oriented towards population-level ana-
lyses that are linked to forms of epidemiologic inquiry, and survey-
based data ﬁndings. In comparison, relatively few studies have
explored non-medical prescription drug use and processes of drug
diversion in terms of the smaller-scale social and interpersonal
dynamics underlying these broad patterns of consumption. The
present analysis is based on the hypothesis that ﬁne-grained so-
ciocultural approaches may be valuable for understanding the local
particularities and processes from which population-level trends
arise (Quintero et al., 2006).
An example of such a socio-cultural approach is provided by the
anthropologist Anne Lovell and her ethnographic analysis of the
‘pharmaceutical leakage’ (2006) that arises in relation to bupre-
norphine diversion in France. While predominantly oriented to-
ward the speciﬁc case of buprenorphine use and exchange among
her informants, Lovell's study may be takendas it is heredas a
starting point for considering how patterns of national drug
diversion can be investigated at the micro level as a social and
interactive phenomenon. For example, Lovell suggests that phar-
maceutical diversionmight be described as a process that ‘connects
the doctor's ofﬁce or the pharmacy with networks of drug users
who can diffuse the product and knowledge about it’ (2006: 156).
While Lovell fully recognizes that local actors' activities are tied to
broad cultural dynamics and political-economic systems, one of her
most crucial ﬁndings is that macro-level patterns cannot be fully
understood without an account of the everyday beliefs and actions
of individuals who seek, receive, and distribute diverted pharma-
ceuticals: the different practices and strategies associated with
acquiring medications, as well as the intersubjective un-
derstandings and local knowledges that circulate with them. The
novelty of such a perspective, in comparison to many other ana-
lyses of drug diversion, is that it places emphasis on developing an
empirical account of the everyday practices that arise as pharma-
ceutical products ‘leak’ out from the legalised ﬂows of industrial
production and medically-condoned distribution, to the illicit
realm of black-market distribution and non-medical use.
The analysis below takes inspiration from sociocultural analyses
such as Lovell's insofar as it approaches drug diversion as a social
process to be explained, rather than as an epidemiological pattern to
bemeasured. Exploring themechanisms throughwhich prescription
psychostimulants are acquired and exchanged among students on an
elite American university campus, it focuses in particular on what
Lovell describes as ‘the pharmaco-associative’, that is, ‘the indige-
nous transmission and elaboration of knowledge about psychoactive
substances and the ongoing interaction and ensuing social organi-
zation of the drug users themselves’ (2006: 156). After providing an
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which may be considered as representations of different forms of
‘pharmaco-association’ that appear among users, as these relate to
individuals' strategies for obtaining Adderall for illicit, non-medical
purposes. A subsequent discussion further considers how the
everyday circumstances, shared meanings and social practices that
are reported may be linked to ‘translocal’ processes, including those
associated with contemporary conﬁgurations of medical knowledge
and clinical practice, national regulatory apparatuses, and commer-
cial pharmaceutical enterprise.
Beyond developing insights on the speciﬁc case of illicit,
nonmedical use of prescription stimulants, a subsidiary aim of the
current paper is to contribute to ﬁne-grained, micro-level studies of
‘pharmaceuticalization’ that explore the social, personal and
everyday dynamics that arise as pharmaceutical products come to
be put to work in the management of an increasingly wide array of
problems and experiences. In line with contemporary empirically-
oriented approaches, pharmceuticalization is understood here as a
‘dynamic and complex heterogeneous socio-technical process’
(Williams et al., 2011: 721) linked to increasing rates of pharma-
ceutical consumption (Bell and Figert, 2012; Busﬁeld, 2010); and I
suggest that qualitative approaches attuned to everyday consumer
practices hold signiﬁcant potential for contributing to un-
derstandings of how individuals and consumer experiences inter-
sect with broader political and economic dynamics (Fox et al.,
2005; Jones, 2008; Stevenson et al., 2008).
1.2. Methods and data analysis
Findings presented here were generated from a qualitative
investigation conducted by the author over a three-year period
(2009e2011). Data was collected over 5 months of ﬁeldwork at an
elite US university, involving thirty-eight semi-structured in-
terviews designed to elicit informal conversation about the beliefs,
practices, and experiences of non-medical users (17 women, 21
men) of prescription stimulants. Initial subjects were recruited
through posters placed in student areas on the university campus,
and through a call for participants circulated via an email listserv
run by the university; snowball sampling was also subsequently
used, as participants informed friends, acquaintances, and col-
leagues about the study. Research and consent procedures were
reviewed and approved by the university's IRB.
Recruitment materials requested participants who had experi-
ence using Ritalin, Adderall, or other medications as ‘study aids’,
and to be included in the dataset used for the following analysis
participants had to: (1) be a former or current university student;
(2) have experience using prescription stimulants as a means of
improving academic performance, over a period of at least 3
months; and (3) not self-identify as having ADHD or any other
psychiatric condition associated with impaired academic perfor-
mance. Interviews were recorded and transcribed in full, and
transcripts were imported into the qualitative analysis software
Nvivo (Bazeley, 2007). Consonant with a grounded theory approach
(Charmaz, 2006), data were coded and analytic induction used to
identify key themes. Informants reported using a number of
different medications, including Ritalin, Concerta, and Dexedrine,
but the analysis below focuses on one particular productdnamely
Adderalldas this was what the overwhelming majority of subjects
reported experiences with. In order to ensure anonymity, pseudo-
nyms have been used for all informants' names.
2. Results
As a result of preliminary analysis of data, variation in the
sources fromwhich individuals obtained Adderall was identiﬁed asa signiﬁcant theme, relating to differences in informants' practises
and experiences with the drug. Subsequent analysis identiﬁed four
different sources, each of which was in turn associated with
different ‘acquisition strategies’ that individuals employed in order
to obtain medication for non-therapeutic use. Two of the strategies
involved gift-like exchanges of Adderall, in which medication was
obtained from friends or family members without any ﬁnancial
payment. Another two strategies involved the procurement of
Adderall in relation to commercial transactions, either through
involvement in local black markets, or by accessing legal pharma-
ceutical markets after having fraudulently obtained a doctor's
prescription. Every one of the individuals interviewed reported
experiences relating to one or more of these four themes.2.1. Acquisition from friends
The most common way that informants reported obtaining
Adderall for non-medical use involved receiving pills from some-
one known personally to them, and well enough to be described as
a friend. More than three-quarters of individuals (n29) reported
such transactions, in which a recipient would typically be given a
small supply of pills without expectation of a monetary payment or
other ﬁnancial exchange. Such gifts would usually, although not
always, come from individuals who themselves had a prescription
for the medication; and they would normally consist of no more
than a few pillsdoften, only one or two which would be expected
to be consumed on a single occasion.
The fact that pills were provided only a few at a time meant that
regular use depended on continuous offerings being made to an
individual. At the same time, however, direct requests for Adderall
were largely avoided, as these were considered likely to give rise to
uncomfortable situationsdfor example, a person making an
explicit request might be perceived as greedy or presumptuous, or
might risk putting a friend in the awkward position of having to
refuse an appeal for help. Thus, more circumspect tactics were
considered to be called for, particularly if one was hoping to receive
pills on a regular basis.
During a discussion of how he acquires his medications, Jas, an
undergraduate science major, offers a typical account of such a
pattern of exchange, and alludes to ‘scrounging’ behaviours that are
involved:
JAS: That ﬁrst time, a friend gave me ﬁve 10-mg pills and I broke
them in half, so it was ten days' worth and went from there.
INTERVIEWER: And that's how you get them now, the same
way?
JAS:Well, I don't ask, like I did then. It's more scrounging around
from the friends that I know have lots of extras. Like I said,
people get prescribed signiﬁcantly more than they actually use.
IV: So you don't normally ask them?
JAS: No. Asking all the time, that would be… I just make sure, I
do what I can so that it’ll be offered.
Individuals reported a variety of similar ‘scrounging’ practices,
directed towards individuals known to have supplies that might be
shared, and performed in the hopes of yielding an offer of medi-
cation. Most commonly, informants reported dropping hints in
conversations that could be picked up on by a receptive interloc-
utor. For example, Estelle explains the efforts she made after having
received Adderall from a friend for the ﬁrst time:
ESTELLE: What I did was, afterwards, I made it very clear that I
was open tomore. ‘Oh, you know, it was amazing, it made things
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the time, I'm so jealous!’ And she got the message. It was pretty
obvious.
IV: But not as obvious as, say, just asking her?
ESTELLE: No. I didn't do that. I didn't know how she would feel,
you know? And even now [after regular, ongoing exchanges], I
just wouldn't. I just let her know, keep on telling her how great
she isdand how great it is!
In addition to discussing beneﬁts derived from Adderall, and
voicing appreciation of gifts, individuals might also emphasize
stresses or worries about difﬁcult workloads. Anna explains how she
does thisdeliberately,whenattempting toelicit anoffer froma friend:
ANNA: I'll just steer the conversation toward that, and say
something like, ‘I don't knowwhat to do, in the next 3weeks I've
got a paper for English, one for History, a report for Bio; and
three killer ﬁnals, too. It's soooo much…’
In a similar vein, Jeff explains how to present an account of one's
academic troubles in amanner likely to lead to an offer of assistance
in the form of medication:
JEFF: You just make it clear that you’re in over your head, like,
‘I'm in deep shit here!’, and you drive it home. Eventually, if he's
got some, he’ll feel bad keeping it to himself, when he knows he
can help you out. If he can manage, he’ll offer you some. Or, at
least, he'll say ‘sorryman, I've only got enough forme right now’,
and then you know, you can move on and try elsewhere.
While the deliberate management of conversational exchanges
was the most commonly reported scrounging strategy, some in-
dividuals described practices oriented toward fostering emotional
and/or spatial closeness between donor and recipient. For example,
Aiden tells me that he makes a point of being present with a friend
at timeswhen she is likely to be taking Adderall herself. Physical co-
presence, a shared social experience, and feelings of togetherness
among ‘study buddies’ leads to Adderall exchanging hands:
AIDEN: I don't ask, or even hint much, really. I just, I know the
days she tends to be on it; and so I'm like, ‘Oh, hey, I'm going to
hit the books todaydwhat, you are too? Well, we should hang
out!’ And when she's going to take some, she’ll just look at me
and smile, and look at the bottle. And I'll shrug, sort of to say,
‘well, ok, sure I guess.’
Despite variations in these different tactics, this group of
friendship-oriented, gift-seeking practices share in common signif-
icant features that are captured by Jas's felicitous use of the term
‘scrounging,’ above. They involve attempts to identify and subtly
manipulate sources fromwhich medication can be obtained for free;
they are associated with a sense of uncertainty that is experienced in
the face of a more or less unreliable supply; and they tend to reﬂect a
dependence on the beneﬁcence of others that must be actively
encouraged. Moreover, informants often acknowledged that how-
ever subtle such strategies might be, they involved amanipulation of
one's friends.While seldom relished, this was considered a necessary
part of what needed to be done to obtain the pills that were sought.2.2. Acquisition from family members
A related though less common set of practices (reported by nine
participants) involved the acquisition of Adderall from familymembers or intimate partners. Exchanges of Adderall through
family connections resembled gift transactions among friends, in-
sofar as they took place in the absence of monetary exchange.
However, family-oriented strategies often involved practices that
would be regarded as unsuitable or unthinkable if directed toward
friends. Most notably, informants indicated that the sort of explicit
request for Adderall that was difﬁcult to make to a friend could be
made with relative ease to a family member.
In response to a question about how he obtains Adderall from a
brother who uses it as a prescribed treatment for ADHD, for
example, James explains why he feels able to make requests
directly:
IV: So you just ask him for it, and he gives it to you?
JAMES: Yeah, of course. I mean, he has plenty, and it's not like he
would be like, ‘nodit’s mine!’ He just wouldn't, we’re not like
that. And it's his prescription, ok, but it's like, my Dad's insur-
ance is what pays for it.
IV: And he doesn't have any problem… You know, even though
you don't have ADHD?
JAMES: No. I mean, he knows that he takes it and it helps him
with school. And he knows that if he gives it to me, it helps me
with my stuff, too. What does it matter, who's got the diagnosis?
It's like: you’ve got something, it helps, can help me. Of course
you’re going to share.
For James, Adderall appears to be considered something akin to
a collectively owned, family good. James suggests that even if the
pills he receives are, in one sense, a gift from his brother, they are at
the same time not really his brother's to give, since they are paid for
by his family's medical plan. Moreover, as our conversation
continued, it became apparent that James' receipt of Adderall was
not accompanied by any signiﬁcant sense of gratitude or reciprocal
obligation. Sharing between family members was expected as a
matter of course.
Other informants indicated that family members with legiti-
mate prescriptions could be less willing to share than was James'
brother; in fact, some even resisted demands placed upon them.
However, in such cases the nature of the close ties between seeker
and potential supplier seemed to allow direct strategies of
manipulation to be used, without giving rise to the negative feel-
ings associated with scrounging from friends. For example, Adam, a
social science undergraduate, tells me that it's not a big deal for him
to ‘guilt-trip’ his girlfriend of several years into giving up some of
her prescribed supply. ‘She does get a little weirded out by it [a
direct request], but she’ll eventually go along’, he says as he ex-
plains a typical situation inwhich he asks for some Adderall to help
him through an end-of-semester crunch. ‘I’ll be, “Look, don't you
want me to do well? I need it, I need to ace these. It's my future
we’re talking about here.” And she’ll be, “Ok…”.’
Perhaps the clearest indication of the distinct quality of family-
oriented acquisition strategies was the fact that practices extending
beyond emotional manipulation could be entertained as
optionsdincluding behaviours reported by two individuals that
might be considered theft. Frieda, for instance, tells me that she
obtains her study pills while returning to her family home during
holidays or other breaks. During such visits, she surreptitiously
goes into the family medicine cabinet and ‘skims’ pills from bottles
of medication that are intended for her ADHD-diagnosed little
sister. Although she does confess feeling guilty about such behav-
iour, Frieda nevertheless feels able to obtain Adderall from her
sister in a way that she insists she would never consider in relation
to a friend. When I ask her whether she has ‘skimmed’ pills from a
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emphatically telling me: “No way, I would neverdthat would be
stealing. I mean, for real.” Similar to James, Frieda appears to regard
a family member's supply of medication as something akin to
communal property, a share of which one might more or less
rightfully expect.
2.3. Acquisition from black market sources
Eight individuals reported paying cash for pills from those
willing to sell them onwhatwas, in essence, a blackmarket existing
within and around the university campus. Practices oriented to
these sources diverged from those outlined above, insofar as they
involved monetary exchange, and tended to involve more imper-
sonal interactions as are generally associated with market-oriented
transactions. This was especially apparent in cases that involved
buying Adderall from individuals described as campus-based ‘drug
dealers’: While the main trade of such dealers consisted of recre-
ational street drugs such as marijuana and cocaine, they could also
provide Adderall and other prescription drugs, through trans-
actions that were almost entirely business-like in terms of their
impersonality.
However, distinctions between market and non-market ex-
changes appeared much less clear-cut in relation to the most
frequently reported black-market transactions; these (reported by
seven individuals) involved the purchase of Adderall not from
‘dealers’, but from students who were situated within a buyer's
extended social networks. Such suppliers tended to be described in
familiar and relatively informal terms, for example as someone that
one ‘sort of knows’, or as a ‘friend-of-a-friend.’ At the same time,
however, the distance between exchanging partners was such that
the employment of strategies used for acquiring Adderall as a gift
would not be considered viable. Whereas friends might be
approached with the hope of receiving pills for free, receipt of
Adderall from acquaintances could only be expected in exchange
for payment.
The acquisition of black market Adderall from acquaintances
was not always easy, as connections to sellers were most often
made through mutual friends. This meant that locating
acquaintance-based sources would usually depend on the ability of
a potential buyer to mobilise personal networks, as Jeff, indicates
when explaining the strategy he uses when he is unable to obtain
pills for free:
JEFF: I'll just ask around, ‘hey, I want to stock up a bit for end of
termedo you know anyone who's got some that they'd be
willing to part with?’ And they'll ask how much I'm willing to
pay, and then ask around, if they know anyone who has it’
The nature of resulting transactions was somewhat ambiguous,
insofar as these blurred distinctions between market and gift re-
lations. Reliance upon friends who were willing to help ﬁnd a
source meant that buyers often experienced uncertainty about the
reliability of their supplies; moreover, to the extent that successful
acquisition were dependent upon the goodwill of connection-
making friends, it might call for interpersonal efforts akin to
those involved when scrounging gifts. At the same time, pills ob-
tained from acquaintances could usually be purchased more
cheaply than those bought from a dealer, with prices sometimes so
lowdfor example, just enough to cover the costs that an acquain-
tance would have incurred at a pharmacydas to be almost gift-like.
A notable feature of market-oriented acquisition strategies was
their association with particular beliefs and understandings about
what purchased Adderall might reveal about its users. While one
might expect market-oriented exchanges to be a preferred means ofacquisition, to the extent that they could offer more impersonal
transactions and increased reliability of supplies, most individuals
expressed a strong preference for gifted Adderall. Rather than being
linked to concerns about ﬁnancial cost, this preference was usually
articulated in connectionwith the belief that someonewhowould go
so far as buying pills might be too dependent on them; the implicit
expectation being that one ought to be able to take Adderall or leave
it, and only take it when it came for free. Purchased Adderall also
tended to be associated with subtle but signiﬁcant meanings that
differentiated it from Adderall received as a gift: when purchased, it
was something that seemed more like a ‘drug,’ with connotations of
street use, danger, and outright illegality, and less like a ‘medication,’
which by comparison was perceived as relatively safe and socially
accepted. Moreover, those who had never paid for the medication
often emphasised that fact, in such a way as to imply a signiﬁcant
distinction between themselves and others who had.2.4. Acquisition from deceived clinicians
A separate set of market-oriented acquisition strategies involved
the extraction of Adderall for non-medical use from legal pharma-
ceutical markets, through means of clinical deception. Four in-
dividuals reported obtaining Adderall as a result of carefully-planned,
fraudulent encounters with healthcare providers. These involved
strategies oriented toward deliberately manipulating physicians in a
way thatwould lead towarda (false)diagnosisofADHD,which in turn
would result in a prescription for the desired medication.
One such encounter was described by Lucy, a second-year un-
dergraduatewho explained tome howher plans had developed out
of a visit to her doctor, regarding what she believed to be depres-
sion. Lucy had reported several psychiatric symptoms relating to
low mood, but also one which led her clinician to raise the possi-
bility of prescribing a stimulant medication:
LUCY: I told her about the problem, of feeling really down, and
sometimes crying and stuff. But I also mentioned that I was
having concentration problemsdand she said, ‘oh it might be
ADD [Attention-Deﬁcit Disorder]. But, you know, we’re going to
put you on anti-depressants ﬁrst.’
Although Lucy did not consider there to be any chance that she
actually had ADD, she had in fact already been using gifted Adderall
to help her study. She thus seized upon her doctor's mention of
ADD as an opportunity to access a new, more reliable source of
Adderall. After a few months on antidepressants, she returned to
her doctor with this plan in mind. ‘I just used that’, she explained,
referring to the physician's prior speculation about ADD. ‘I said, oh
yeah, well, you know, that anti-depressants are really working, but
I'm still having trouble concentrating on my work.’ Believing it
would ‘play better’ if she did not appear too eager, Lucy describes
feigning resistance in response to the clinician's suggestion that her
antidepressant be supplemented with an ADHD medication:
LUCY: I just played into the whole fact of being like [… ] nervous
about taking the medication. And, you know, she kept soothing
me and saying, “no, no, no, like, you know, lots of people take
medication for it, it's absolutely ﬁne, you know, we're just going
to start you off low, we’ll see how it goes, and you know, see how
you responded, youmight not respond to it at ﬁrst so if you need
to increase it, you know, that's ﬁne, we’ll talk about thatdcome
back next week.”
Informing me that this was ‘exactly what I wanted’, Lucy went
on to explain how, over a series of subsequent appointments, she
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prescribed dosage. This provided her with more pills than she
herself regularly used, and thus with a surplus that she could sell to
others on campus, in order to recoup the costs she incurred when
paying to have her prescription ﬁlled at her pharmacy.
Three other individuals described similar approaches involving
deliberate deception, although without any prior discussion of
ADHD or stimulant medications with their doctors. Aaron, for
example, told me about a strategy he developed after hearing ‘good
things’ about non-medical Adderall use from those around him on
campus. Feeling uncomfortable about requesting the drug from his
friends, he conducted research online that led him to decide to try
‘faking’ ADHD symptoms. Preparations for deceiving his doctor
included studying ADHD diagnosis criteria, and using a pen to
scrawl a variety of notes and reminders on his hands immediately
before his appointment, in the hope that these would be noticed as
a symptomdhe had learned that ‘people with ADD or whatever
have trouble keeping track of stuff, they forget a lot.’ Following a
successful encounter, Aaron left his doctor's ofﬁce with an initial
prescription for a month's supply, which was subsequently
renewed on a regular basis.
While only four individuals engaged in this strategy, it is notable
that they all reported using Adderall on a more frequent basis than
did those who acquired the medication from other sources. No
respondents reported taking Adderall on a daily basis for more than
a few consecutive days, when receiving it as a gift or purchasing
black market supplies. Yet all four of the individuals who obtained
their own prescriptions did: two reported having previously taken
the medication everyday for several weeks in a row before estab-
lishing their current patterns of intermittent use, while two re-
ported patterns of daily use that had been maintained for more
than three months. One reason for this tendency toward more
regular use appeared to relate to the fact these individuals found
themselves with a steady and ample supply of the medication. An
illustration of the signiﬁcance of reliability associated with
prescription-sourced Adderall was provided by Marcus, who de-
scribes how his everyday decision-making process changed as he
switched from acquiring Adderall irregularly from friends to
obtaining it via his own prescription: ‘Before, it had been “should I
take some today, or may be save it when I’ll need it more?” But now,
it's more like, I ask myself: “why not take it?” Once a prescription
holder, Marcus did not experience anxieties relating to medication
scarcity that arose when scrounging for Adderall from friends, and
felt able to take pills freely, without a need to consider rationing his
supplies.
3. Discussion
The preceding analysis provides insights into the experiences,
practices and perspectives of non-medical Adderall users, and re-
sults suggest that the means through which non-medical users
obtain their supplies of medication are characterised by a signiﬁ-
cant degree of complexity and heterogeneity. This diversity is
particularly striking if non-medical acquisition strategies are
compared to the simplicity of how Adderall is obtained when le-
gally prescribed to patients as a therapeutic intervention. Legiti-
mately prescribed patients would generally proceed along a
predictable pathway, taking a prescription obtained in the clinic to
a pharmacy, where it would be exchanged for medication. In
contrast, practices of drug acquisition among non-medical users of
Adderall appear to bemuch less standardized, varying considerably
in relation to the particular social and everyday circumstances in
which individuals ﬁnd themselves. Moreover, the use of different
strategies for non-medical Adderall acquisition appears to corre-
spond to subtle but signiﬁcant differences in users' perceptions andexperiences: Adderall bought from a ‘drug dealer,’ for example, is
likely to be perceived differently from that received from a friend
for free or from a doctor that has been tricked into providing it; and
each different source of the medication is associated with a slightly
different set of practical and ethical challenges with which an in-
dividual might be required to engage.
Findings of such diversity among different users is certainly
consonant with well-established scholarship that indicates that the
choices, behaviours and experiences of individual drug users vary
according to the particular circumstances and local conditions
withinwhich individuals ﬁnd themselves (Fraser andMoore, 2011).
They also offer support for recent suggestions that prescription
drug diversion is a complex and multi-faceted phenomenon,
involving considerable variation between different classes of
medication, and between different subpopulations of users (Fischer
et al., 2010; Quintero et al., 2006). Moreover, such insights into the
experiences, practices and perspectives of nonmedical stimulant
users as provided above would seem necessary for developing an
empirically-grounded understanding of the circulation and use of
prescription stimulants among ‘healthy’ university students: It
would be difﬁcult to understand the relatively free movement and
use of nonmedical Adderall among my informants, for example,
without taking into account the practical strategies that make the
substance accessible, and the particular understandings held by
students that make the drug appear as something more or less
acceptable to illicitly acquire and consume.
At the same time that the preceding results and analysis have
explored the signiﬁcance of local and everyday phenomena asso-
ciated with drug diversion, it is important to note that the everyday
beliefs and actions of individuals who seek, receive, and distribute
unprescribed medications such as Adderall are also connected to
larger cultural and political-economic dynamicsdincluding those
associated with the provision of national healthcare, scientiﬁc en-
terprise, and legal pharmaceutical markets. For example, as Lovell
(2006) observes in relation to her study of buprenorphine diver-
sion, the existence of medications as black market goods depends
upon the medical knowledges and regulatory mechanisms that
allow for the legal production and provision of those substances:
these are required to make a pharmaceutical product's very exis-
tence possible, and in their absence there would be no legitimate
commodity to divert from a legal market.
In relation to Adderall, the pharmaceutical markets that exist for
the legal circulation of stimulant drugs can be considered to pro-
vide one of the most basic necessary conditions for students' illegal
trades. Moreover, empirical evidence of a close interrelationship
between legal markets and illicit use is suggested by recent
research that has begun to identify correlations between the overall
size of legal markets for prescription stimulants and rates of non-
medical use of such drugs. Poulin (2007), for example, reports
population-level ﬁndings from Canada that suggested that patterns
of medical and non-medical use of prescription stimulants were
closely connected with one another. Further support is also pro-
vided by ﬁndings of longitudinal survey research conducted by
McCabe et al. (2014), which demonstrate that a decade-long in-
crease in reports of medical use of prescription stimulants to treat
ADHD correlated with a comparable increase in reported diversion
behaviours and non-medical use.
It thus seems reasonable to suggest that the experiences and
practises of the individuals reported above are intertwined with
broader commercial and professional dynamics that studies of
pharmaceuticalization have identiﬁed in relation to the growth of
markets for ADHD drugs. These would include the economic and
regulatory factors that have shaped ADHD as a clinical entity, and
have produced a ‘diagnostic expansion’ in recent years that has
allowed a wider range of individuals to qualify for legal access to
S. Vrecko / Social Science & Medicine 131 (2015) 297e304 303prescription stimulants (Conrad and Potter, 2000). Within the US,
they would also include the inﬂuence of Direct-to-Consumer ad-
vertisements, forms of consumer-group activism, and other initia-
tives ﬁnanced by pharmaceutical companies that may directly or
indirectly promote medication use, and also reinforce perceptions
of psycho-stimulant pharmaceuticals as relatively safe, health-
enhancing substances (Cohen, 2006; Loe and Cuttino, 2008).
3.1. Limitations of current study
The ﬁndings presented above reﬂect limitations that often arise
in relation to qualitative and naturalistic research, particularly
when conducted on a relatively small scale. While providing rich
information pertaining to understandings of and interactions be-
tween individuals, the fact that research was conducted on only
one university campus make it difﬁcult to stake convincing claims
about generalizability of results in relation to other contexts, both
within and beyond the US. Moreover, use of semi-structured in-
terviews raises the potential for unintended interview effects,
whereby informants may offer what they consider to be socially
desirable responses, rather than truthful ones. Finally, the use of
non-randomised sampling procedures means that the population
under study cannot be taken as representative of all students at the
university where the study took place, and also raises the possi-
bility of self-selection bias.
4. Conclusion
This article has presented ﬁndings that add to existing knowl-
edge about prescription drug diversion, by elucidating some of the
everyday practises and understandings that arise in relation to the
non-medical use of stimulant medications among university
studentsda population that has been associated with particularly
pronounced levels of such use (Quintero et al., 2006). It has shown
that signiﬁcant divergences in users' practices and experiences of
nonmedical stimulant use arise in relation to acquisition strategies
employed by individuals, as these relate to the four sources of illicit
medication supplies that were most commonly reported (i.e.,
friends; family members; black market dealers; deceived clini-
cians). It has further shown that different acquisition strategies
correspond to variations in how individuals think and feel about
their nonmedical drug usage. Combined, the reported ﬁndings
suggest that how and why prescription stimulants are used may
vary signiﬁcantly between individuals, even when they might su-
perﬁcially appear to constitute a single, homogenous population
(e.g., university students consuming stimulants for the non-
medical purpose of improving academic performance). Such ﬁnd-
ings are signiﬁcant because they indicate that nonmedical pre-
scription stimulant is a phenomenon that involves a greater degree
of complexity than might be apparent from consideration of sta-
tistical or population-level data.
While ﬁndings relating to the particularities of users' everyday
experiences and practises might be dismissed as relatively unim-
portant details by those experts and agencies that seek to address
public health issues associated with nonmedical prescription drug
use, such a dismissal would be misguided. Indeed, if social cir-
cumstances and individual contingencies do in fact constitute sig-
niﬁcant factors in determining how and why students come to take
prescription stimulants, then a better understanding of these
would be helpful in relation to the consideration of ethical, regu-
latory, and public health questions arising in relation to nonmedical
stimulant use. As Quintero et al. (2006) note, surveillance data and
media reports suggest signiﬁcant trends in prescription drug
misuse among university students, yet little is known about social
and cultural factors that shape individuals' practices. This dearth ofknowledge is signiﬁcant, because detailed understandings of how
drug diversion happenswithin different groups of usersmight be of
signiﬁcant value in relation to education and prevention initiatives
that seek to change individual behaviours, particularly if these are
best developed in such a way that takes individual-level variations
into account (Wilens et al., 2008). For example, ﬁndings above
might be useful in devising initiatives that are speciﬁcally oriented
to different practices of drug diversion that arise in relation to
different sources of supply and related acquisition strategies.
It is worth reiterating that the study reported here was con-
ducted at a single university, and therefore provides ﬁndings that
are limited in their generalizability. Nevertheless, results suggest
fruitful avenues for further research on non-medical prescription
stimulant use. Future studies might pursue more systematically the
ﬁndings reported above that suggest that divergences in the
acquisition strategies that are employed by individuals correspond
to differences in how users think and feel about Adderall. More
broadly, ﬁndings above suggest that further use of sociocultural
research strategies could increase understandings of how drug
diversion happens among the individuals and groups who actively
engage in the illicit use and exchange of pharmaceutical products.
A further avenue for research would involve exploring in more
detail the potential of Lovell's concept of ‘pharmaceutical leakage’
for contributing to studies of ‘pharmaceuticalization’ that examine
the expanding usage of medications within a wide range of per-
sonal and socio-medical contexts (Bell and Figert, 2012)dand
particularly those which seek to understand pharmceuticalization
as a complex, multi-faceted social and medical process (Williams
et al., 2011). Lovell develops her ideas exclusively in relation to
buprenorphine users in France, with little discussion of other
medications. However, the analysis above suggests that her
framework has applicability to cases beyond that of buprenor-
phine; it may be particularly useful in extending analyses of how
individual and consumer experiences intersect with broader po-
litical and economic dynamics (Fox et al., 2005; Jones, 2008;
Stevenson et al., 2008). It has been suggested that recent studies
of pharmaceutical research, development and commerce (e.g.,
Petryna, 2009; Pollock, 2012; Wahlberg and McGoey, 2007) indi-
cate that the pharmaceutical industry is a complex and multi-
faceted entity akin to a massive elephant whose form can only be
grasped in parts at a time (Dumit, 2012: 18). With its orientation
toward investigating how globally produced and marketed prod-
ucts enter into the circuits of everyday use, and how effects and
meanings of pharmaceuticals are mediated by the personal and
social circumstances of individual who consume them, Lovell's
approach might allow for the dynamics of pharmaceutical industry
to be understood in even greater complexity, as extending down
into the everyday worlds of those who consume the industry's
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